Summary
A group of 13 patients with acute myeloid leukaemia of differing disease status were treated with continuous intravenous infusion of high-dose recombinant interleukin-2 (rIL-2). There was up-regulation of the cellular cytotoxic functions in all these patients following the rIL-2 therapy, with increase in the natural killer (NK) activity, lectin-dependent cellular cytotoxicity, induction of cytotoxicity-linked cytoplasmic serine esterase and lymphocyte activation. However, the clinical response to rIL-2 in these patients was disappointing, especially in patients treated in frank relapse. Although 1 patient treated in early second relapse achieved a third complete remission, the duration of the remission was brief and lasted only 6 months. Adverse reactions among these patients were common. Whether or not lymphokine-activated killer cells are needed to improve the response rate over rIL-2 alone in these patients deserves further investigation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adler A, Chervenick IA, Whiteside T, Lotzova E, Herberman RB (1988) Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 71: 709–716
Barrett AJ (1989) IL-2 in treatment of haematological malignancies. Presented at the Grantholder's meeting, Leukaemia Research Fund, London, November 1989
Beran M, Hansson M, Kiessling R (1983) Human natural killer cells can inhibit clonogenic growth of fresh leukemic cells. Blood 61: 596–599
Champlin RE, Ho WG, Gale RP, et al (1985) Treatment of acute myelogenous leukemia: a prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med 102: 285–291
Fletcher M, Goldstone AL (1987) Recent advances in the understanding of the biochemistry and clinical pharmacology of interleukin-2. Lymphokine Res 6: 45–57
Foa R, Meloni G, Tosti S, et al (1990) Treatment of residual disease in acute leukemia patients with recombinant interleukin-2 (IL-2): clinical and biological findings. Bone Marrow Transplant 6 [Suppl 1]: 98–102
Foa R, Caretto P, Fierro MT, et al (1990) Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin. Br J Haematol 75: 34–40
Gillis S, Smith KA (1977) Long-term culture of tumour-specific cytotoxic T-cells. Nature 268: 154–156
Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumour cells by interleukin 2-activated autologous human peripheral blood. J Exp Med 155: 1823–1841
Henney CS, Kurybayashi K, Kern DE, Gillis S (1981) Interleukin-2 augments natural killer cell activity. Nature 291: 335–338
Lafreniere R, Rosenberg SA (1985) Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res 45: 3735–3741
Lim SH, Callaghan T, Goldstone AH (1991) Thyroid disorders in two cases of AML following treatment with recombinant interleukin-2. Acta Hematol (Basel) 85: 49–50
Lim SH, Worman CP, Jewell AP, Goldstone AH (1991) Cellular cytotoxic function and potential in acute myelogenous leukaemia. Leuk Res 15: 6411–6444
Lim SH, Worman CP, Jewell A, Tsakona C, Giles FJ, Goldstone AH (1991) Lymphocytes activation and serine esterase induction following recombinant interleukin-2 infusion for lymphoma and acute leukaemias. Cancer Immunol Immunother 33: 133–137
Lim SH, Worman CP, Jewell AP, Goldstone AH (1991) Production of tumour-derived suppressor factor in patients with acute myeloid leukaemia. Leuk Res 15: 263–268
Lista P, Fierro MT, Liao XS, et al (1989) Lymphokine-activated killer (LAK) cells inhibit the clonogenic growth of human leukaemia stem cells. Eur J Haematol 42: 425–430
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Mule JJ, Shu S, Schwarz SL, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 255: 1487–1489
Powles RL, Morgenstern G, Clink HM (1980) The place of bone marrow transplantation in acute myelogenous leukaemia. Lancet 1: 1047–1050
Price G, Brenner MK, Prentice HG, Hoffbrand AV, Newland AC (1987) Cytotoxic effects of tumour necrosis factor and gamma-interferon on acute myeloid leukemia blasts. Cancer 55: 287–290
Rees JKH, Gray RG, Swirsky E, Hayhoe FGJ (1986) Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 2: 1236–1241
Rosenberg SA, Lotze MT, Muul LM, et al (1985) Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485–1492
Rosenberg SA, Lotze MT, Muul LM, et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889–897
Rosenstein M, Yron I, Kaufmann Y, Rosenberg SA (1984) Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine lymphocytes cultured in interleukin-2. Cancer Res 44: 1946–1953
West WH, Tauer KW, Yanelli JR, et al (1987) Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898–905
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lim, S.H., Newland, A.C., Kelsey, S. et al. Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia — a phase II study. Cancer Immunol Immunother 34, 337–342 (1992). https://doi.org/10.1007/BF01741555
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01741555